/stocks — the workspaceLOADING
SUPERNUS PHARMACEUTICALS, INC. (SUPN) is a pharmaceutical preparations company. Piotroski F-Score 4/8. Next earnings projected around 2026-07-21 from SUPN's year-over-year reporting pattern (not yet company-confirmed). Fundamentals from SEC filings; prices are end-of-day.
EOD daily bars · delayed, not real-time · data: DatabentoCharting by TradingView Lightweight Charts™
XBRL company facts, SEC EDGAR. TTM = last four reported quarters. Valuation ratios arrive with a price source — we don't fake quotes.
FY ending 2025-12-31 vs 2024-12-31. original 1968 formula; calibrated on manufacturers, read financials/REITs with care
A plain-English read on SUPN plus an auto-SWOT — built from SUPN's SEC filings and market data, every point cited, nothing invented. Educational, not investment advice.
Four AI analysts — a bull, a bear, a risk manager, and a PM — debate SUPN using only the SEC-filing and market facts below. Every point cites its evidence; nothing is invented. This is educational research, not investment advice.
Educational only — not financial advice. Data from SEC EDGAR public filings; no live market data is shown. Figures reflect the company's own reported XBRL facts and may lag.
| Third Avenue Management | $7.9M | 1.3% of portfolio |
Projected from SUPN's own SEC 8-K filing history — the year-over-year reporting pattern (~50% land the exact day, ~90% within a week). No analyst estimates, no scraped calendars, nothing invented. It upgrades to a confirmed date + time the moment SUPN files its announcement.
SUPN's earnings reaction has been evenly split — 4 up, 4 down across its last 8 reports.
Earnings reactions have been mild.
A more typical earnings reaction has been approximately ±1.7%.
Realized close-to-close history only — no options-implied move, no analyst estimates.
| Reported | Close-to-close |
|---|---|
| 2026-04-22 | +2.6% |
| 2026-02-12 | -1.0% |
| 2025-10-21 | -1.8% |
| 2025-07-22 | -0.8% |
| 2025-04-23 | +1.7% |
| 2025-02-11 | +2.8% |
| 2024-10-21 |
Earnings dates are the company's 8-K Item 2.02 filings (SEC). Reactions from Databento EOD.
| -2.4% |
| 2024-07-23 | +1.5% |
| Bhatt Padmanabh P.Sr. VP of IP, CSO | SELL | $5.4M | view → |
| Hudson Frederick M.Director | SELL | $272K | view → |
| Khattar Jack A.President, CEO | SELL | $1.8M | view → |
| Horich William ToddSVP, Commercial Operations | SELL | $484K | view → |
| Mottola FrankSVP, Chief Tech. Ops. Officer | SELL | $87K | view → |
| GEMAYEL GEORGESDirector | SELL | $1.0M | view → |
| Sensenig BethanyDirector | SELL | $228K | view → |